Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

HealthRX vs NiceRx

Two GLP-1 desks, one scoreboard. We put HealthRX and NiceRx head-to-head on the published Brief Score — the same six factors, scored the same way.

No. 7 · Grade B

HealthRX

Visit HealthRX Full brief →
vs
No. 20 · Grade B

NiceRx

Visit NiceRx Full brief →

The verdict

Too close to call on the Brief Score.

HealthRX and NiceRx are level at 86/100. The scores won't separate them, so the pick comes down to fit: HealthRX for readers who want an accredited, physician-supervised program with a needle-free oral tablet option on either molecule — and value a legitscript trust signal, while accepting that some tiers are company-stated. NiceRx for readers who want a longer-tenured, accredited name over an unknown newcomer.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
85
85
Supply Reliability
85
86
Transparency
83
87
Access Breadth
91
87
Clinical Oversight
89
86
Track Record
81
84
HealthRXBrief Score 86 · 86NiceRx

Price, coverage & the tracker

HealthRXNiceRx
Brief Score86/100 (B)86/100 (B)
Semaglutide$190/mo month-to-month ($99 first month, renews at $165) · $99/mo on a 12-month prepay ($1,188)$199/mo
Tirzepatide$239/mo month-to-month ($149 first month, renews at $214) · $179/mo on a 12-month prepay ($2,148)$299/mo
CoverageNot publicly listedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
On the trackerStableprice stableStableprice stable

HealthRX: Company-stated tiers held flat this cycle; the LegitScript badge and a rare oral GLP tablet are the draw, but some tiers are self-reported rather than checkout-verified.

NiceRx: $199 sema / $299 tirz nationwide; LegitScript-certified, established operator.

Not sold on either?

CoreAge Rx tops the whole ranking at 94/100.

The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.